galactosamine has been researched along with tamoxifen in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Huang, X; Jiang, Y; Luo, M; Wan, M; Xu, S; Zhang, M; Zhang, P | 1 |
Cao, P; Gong, X; Lin, Y; Liu, L; Luo, M; Wu, T; Yang, Q; Zhou, L | 1 |
2 other study(ies) available for galactosamine and tamoxifen
Article | Year |
---|---|
Tamoxifen Attenuates Lipopolysaccharide/Galactosamine-induced Acute Liver Failure by Antagonizing Hepatic Inflammation and Apoptosis.
Topics: Animals; Apoptosis; Caspase 3; Chemical and Drug Induced Liver Injury; Galactosamine; Humans; Interleukin-1beta; Lipopolysaccharides; Liver; Liver Failure, Acute; Mice; Mice, Inbred BALB C; Tamoxifen; Transaminases; Tumor Necrosis Factor-alpha | 2017 |
Tamoxifen Prevents D-galactosamine/Lipopolysaccharide-Induced Murine Acute Hepatic Failure through Inhibition of Oxidative Stress and Mmd-2 Upregulation.
Topics: Acetylcysteine; Alanine Transaminase; Animals; Antigens, Differentiation; Antioxidants; Aspartate Aminotransferases; Catalase; Galactosamine; Glutathione Peroxidase; Lipopolysaccharides; Liver Failure, Acute; Mice; Mice, Inbred BALB C; Oxidative Stress; Superoxide Dismutase; Tamoxifen; Up-Regulation | 2018 |